Doses - THIOTEPA

Dogs:

For intracavitary use neoplastic effusions or systemically for adjunctive therapy of carcinomas:
a) 0.2 - 0.5 mg/m2 intracavitary; IV. (Jacobs, Lumsden et al. 1992)
Monitoring Parameters - 1) Efficacy; 2) CBC w/platelets
Client Information - Clients must be briefed on the possibilities of severe toxicity developingfrom this drug, including drug-related neoplasms or mortality. Clients should contact veterinarianshould the animal exhibit symptoms of abnormal bleeding, bruising, anorexia, vomiting, jaundice orinfection.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None

Human-Approved Products:

Thiotepa Powder for Injection 15 mg in vials; Thiotepa® (Immunex); (Rx)